Glycation of Glutamate Cysteine Ligase by 2-Deoxy-d-Ribose and its Potential Impact on Chemoresistance in Glioblastoma
- 460 Downloads
The antioxidant glutathione (GSH) plays a critical role in maintaining intracellular redox homeostasis but in tumors the GSH biosynthetic pathway is often dysregulated, contributing to tumor resistance to radiation and chemotherapy. Glutamate-cysteine ligase (GCL) catalyzes the first and rate-limiting reaction in GSH synthesis, and enzyme function is controlled by GSH feedback inhibition or by transcriptional upregulation of the catalytic (GCLC) and modifier (GCLM) subunits. However, it has recently been reported that the activity of GCLC and the formation of GCL can be modified by reactive aldehyde products derived from lipid peroxidation. Due to the susceptibility of GCLC to posttranslational modifications by reactive aldehydes, we examined the potential for 2-deoxy-d-ribose (2dDR) to glycate GCLC and regulate enzyme activity and GCL formation. 2dDR was found to directly modify both GCLC and GCLM in vitro, resulting in a significant inhibition of GCLC and GCL enzyme activity without altering substrate affinity or feedback inhibition. 2dDR-mediated glycation also inhibited GCL subunit heterodimerization and formation of the GCL holoenzyme complex while not causing dissociation of pre-formed holoenzyme. This PTM could be of particular importance in glioblastoma (GBM) where intratumoral necrosis provides an abundance of thymidine, which can be metabolized by thymidine phosphorylase (TP) to form 2dDR. TP is expressed at high levels in human GBM tumors and shRNA knockdown of TP in U87 GBM cells results in a significant increase in cellular GCL enzymatic activity.
KeywordsThymidine phosphorylase Glutamate cysteine ligase 2-Deoxyribose Glutathione Glioblastoma Glycation
Conflict of interest
The authors declare they have no conflict of interest.
- 1.Meloche J, Paulin R, Courboulin A, Lambert C, Barrier M, Bonnet P, Bisserier M, Roy M, Sussman MA, Agharazii M, Bonnet S (2011) RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes. Arterioscler Thromb Vasc Biol 31(9):2114–2124. doi: 10.1161/ATVBAHA.111.230573 PubMedCrossRefGoogle Scholar
- 9.Khalifah RG, Todd P, Booth AA, Yang SX, Mott JD, Hudson BG (1996) Kinetics of nonenzymatic glycation of ribonuclease A leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-Amadori studies. Biochemistry 35(15):4645–4654. doi: 10.1021/bi9525942 PubMedCrossRefGoogle Scholar
- 12.de Bruin M, Smid K, Laan AC, Noordhuis P, Fukushima M, Hoekman K, Pinedo HM, Peters GJ (2003) Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells. Biochem Biophys Res Commun 301(3):675–679PubMedCrossRefGoogle Scholar
- 15.Bijnsdorp IV, Capriotti F, Kruyt FA, Losekoot N, Fukushima M, Griffioen AW, Thijssen VL, Peters GJ (2011) Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors. Br J Cancer 104(7):1185–1192. doi: 10.1038/bjc.2011.74 PubMedCrossRefGoogle Scholar
- 26.Ikeda R, Furukawa T, Kitazono M, Ishitsuka K, Okumura H, Tani A, Sumizawa T, Haraguchi M, Komatsu M, Uchimiya H, Ren XQ, Motoya T, Yamada K, Akiyama S (2002) Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-d-ribose. Biochem Biophys Res Commun 291(4):806–812. doi: 10.1006/bbrc.2002.6432 PubMedCrossRefGoogle Scholar
- 29.Fico A, Manganelli G, Cigliano L, Bergamo P, Abrescia P, Franceschi C, Martini G, Filosa S (2008) 2-deoxy-d-ribose induces apoptosis by inhibiting the synthesis and increasing the efflux of glutathione. Free Radic Biol Med 45(2):211–217. doi: 10.1016/j.freeradbiomed.2008.04.017 PubMedCrossRefGoogle Scholar
- 40.Backos DS, Fritz KS, Roede JR, Petersen DR, Franklin CC (2011) Posttranslational modification and regulation of glutamate-cysteine ligase by the alpha, beta-unsaturated aldehyde 4-hydroxy-2-nonenal. Free Radic Biol Med 50(1):14–26. doi: 10.1016/j.freeradbiomed.2010.10.694c PubMedCrossRefGoogle Scholar
- 42.Backos DS, Brocker CN, Franklin CC (2010) Manipulation of cellular GSH biosynthetic capacity via TAT-mediated protein transduction of wild-type or a dominant-negative mutant of glutamate cysteine ligase alters cell sensitivity to oxidant-induced cytotoxicity. Toxicol Appl Pharmacol 243(1):35–45. doi: 10.1016/j.taap.2009.11.010 PubMedCrossRefGoogle Scholar
- 46.Yoshida S, Yamada K, Hamaguchi K, Nishimura M, Hatakeyama E, Tsuchida H, Sakamoto K, Kashiwabara H, Yokoyama T, Ikeda K, Horiuchi S (1998) Immunohistochemical study of human advanced glycation end-products (AGE) and growth factors in cardiac tissues of patients on maintenance dialysis and with kidney transplantation. Clin Nephrol 49(5):273–280PubMedGoogle Scholar
- 47.Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA, Edwards BK (2011) Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103(9):714–736. doi: 10.1093/jnci/djr077 PubMedCrossRefGoogle Scholar